Pfizer (NYSE:PFE) Hits New 1-Year High – Still a Buy?

Pfizer Inc. (NYSE:PFE)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $28.13 and last traded at $28.2140, with a volume of 6578179 shares. The stock had previously closed at $27.77.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Belgian court ordered Poland and Romania to accept €1.9B (~$2.2B) of Pfizer COVID-19 vaccines, effectively locking in substantial near-term revenue and reducing delivery/collection uncertainty. Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
• Positive Sentiment: Analyst/market write-ups highlight PFE’s recent outperformance and upward technical momentum (trading above its 50- and 200-day SMAs, and positive earnings beats), which supports demand for the stock. Why Pfizer (PFE) Outpaced the Stock Market Today
• Positive Sentiment: Fresh real?world data from a Swedish study on Ibrance (palbociclib) offers an incremental clinical signal for Pfizer’s oncology franchise, supporting pipeline upside expectations. Pfizer’s Swedish Ibrance Study: Fresh Real?World Data Signal for PFE Investors
• Neutral Sentiment: Pfizer finalized reshaping of ViiV Healthcare ownership (GSK/Shionogi deal) as it exits the joint HIV venture — a strategic reallocation that may free capital but reduces direct exposure to that HIV business. GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture
• Neutral Sentiment: Background and business-model pieces continue to circulate (how Pfizer makes money, sector commentary), useful for context but not immediate catalysts. How Pfizer Makes Money
• Negative Sentiment: Pfizer and BioNTech paused U.S. recruitment for a large updated COVID vaccine trial (adults 50–64) due to low enrollment — a setback for collecting pivotal U.S. data and could delay future vaccine updates or label expansion. Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
• Negative Sentiment: Critical pieces argue Pfizer’s large dividend may mask underlying growth challenges, keeping longer-term valuation concerns on investors’ radar. Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem
• Negative Sentiment: Reports that Pfizer will close its South San Francisco research site may signal internal cost-cutting or pipeline reprioritization; this can be seen as short-term disruption to R&D capacity. Pfizer is said to close South San Francisco research site

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Monday, March 2nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. Morgan Stanley set a $27.00 price objective on Pfizer and gave the stock a “positive” rating in a research note on Tuesday, March 17th. TD Cowen restated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Finally, Royal Bank Of Canada initiated coverage on shares of Pfizer in a report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $28.19.

Pfizer Trading Up 1.7%

The firm has a 50 day moving average price of $26.99 and a two-hundred day moving average price of $25.77. The firm has a market capitalization of $162.41 billion, a P/E ratio of 21.00 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same period in the prior year, the firm earned $0.63 earnings per share. The business’s quarterly revenue was down 1.2% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently made changes to their positions in PFE. Horizon Financial Services LLC increased its stake in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new position in Pfizer during the fourth quarter valued at about $26,000. YANKCOM Partnership acquired a new stake in Pfizer in the 4th quarter worth approximately $28,000. HFM Investment Advisors LLC lifted its stake in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the last quarter. Finally, Grey Fox Wealth Advisors LLC bought a new stake in Pfizer during the third quarter valued at about $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.